{"id":4648,"date":"2025-07-30T16:03:18","date_gmt":"2025-07-30T10:33:18","guid":{"rendered":"https:\/\/www.brandcare.net\/blog\/?p=4648"},"modified":"2025-11-07T11:42:53","modified_gmt":"2025-11-07T06:12:53","slug":"drugs-need-identity-too","status":"publish","type":"post","link":"https:\/\/www.brandcare.net\/blog\/drugs-need-identity-too\/","title":{"rendered":"How Drug Identity Shapes Patient Perception and Recognition"},"content":{"rendered":"

Identity in the Indian pharma business is a curious affair. <\/p>\n

It begins with a name, navigates a maze of regulatory hurdles, builds momentum with the logo, peaks with the packaging \u2014 and then quietly fades away.<\/p>\n

Somewhere along the assembly line, identity becomes a checkbox, not a commitment.<\/p>\n

But in a business that trades in healing and hope, identity isn\u2019t just cosmetic.
\nIt\u2019s functional. It\u2019s human. It\u2019s critical.<\/p>\n

Yet in India, that identity rarely survives beyond the strip.<\/p>\n

Take a stroll through any pharmacy. Ask for something common, like paracetamol. The chemist might reach for Parakind, Paraday, Parabliss, or Parafast.<\/em> All legal. All functional. All designed to disappear into the background.<\/p>\n

But just as often \u2014 you\u2019ll hear Crocin or Dolo-650 offered first. That\u2019s no accident.<\/p>\n

Crocin<\/strong>, with its bright red type and cross motif, has long established itself as a household name \u2014 especially in families with children. And Dolo-650<\/strong>, once a prescription brand, rose to cultural prominence during COVID-19, when it became almost shorthand for fever relief. It had the recall, consistency, and wide distribution to back it up \u2014 and its clean, uncluttered packaging stood apart.<\/p>\n

\"\" These aren\u2019t just exceptions. They\u2019re proof thatidentity matters.<\/p>\n

Now shift your gaze to Southeast Asia. Same molecule \u2014paracetamol \u2014 but meet Panadol<\/strong>.<\/p>\n

Unlike most prescription drugs, Panadol is sold OTC in many SEA countries<\/strong>. That regulatory freedom means it can act more like a consumer product \u2014 with advertising, line extensions, and pack-level storytelling. And GSK took full advantage. Panadol Extra, Actifast, Cold & Flu<\/em> \u2014 each has its own color scheme, symptom-specific claims, and even iconography that guides the user.<\/p>\n

Yes, the rules were looser \u2014 but the intent was clearer.<\/p>\n

Then there\u2019s Zyrtec<\/strong>, the antihistamine giant from the U.S. When its patent expired, genericsflooded the market. Zyrtec didn\u2019t change its formula \u2014 it changed its story.
\nIt launched AllergyCast<\/em>, an app that tracks pollen levels, forecasts symptoms, and helpspatients log and share their allergic patterns with doctors. The green-yellow palette, the\u201cstarts working in one hour\u201d claim, the allergy tips across platforms \u2014 all part of an identitysystem that followed the user, not just the prescription.<\/p>\n

Zyrtec is doing its best to ride the generic wave – with memorability.<\/p>\n

Back in Bihar, a small public health project took a different route.<\/p>\n

The team created visual aids<\/strong> to go with the medicines: stickers showing a sun for morning, a moon for night, arrows for dosage, and color codes for urgency. These were handed out by ASHAs in rural health centers.<\/p>\n

The result? Fewer errors. Better adherence.
\nNot branding in the commercial sense \u2014 but identity as accessibility<\/strong>.<\/p>\n

Because sometimes, even a symbol can speak louder than a strip of pills.<\/p>\n

Meanwhile, in Japan, Takeda Pharmaceuticals<\/strong> applied the same principle with surgical precision.<\/p>\n

Their OTC products include resealable pouches, Braille-embossed labels, bold dosage indicators, and color cues \u2014 designed not for style, but for daily usability. Because a product that\u2019s easy to identify is a product that\u2019s easy to trust.<\/p>\n

It\u2019s tempting to say Indian pharma doesn\u2019t care about identity because of regulations. After all, advertising is limited, packaging rules are strict, and prices drive everything. But the global examples show us that constraints don\u2019t kill creativity \u2014 they demand it<\/strong>.<\/p>\n

Revital found a way. Panadol found a way. Zyrtec built a way.<\/p>\n

But patients don\u2019t stop there.
\nThey open that box<\/p>\n

They squint at the strip.
\nThey second-guess the color.
\nThey look for clues \u2014 any clues \u2014 that bring memorability<\/strong>.<\/p>\n

Because most don\u2019t \u2014 and can\u2019t \u2014 recall the name of the drug.
\nNot when it\u2019s Azithrowhat or Met-something-something<\/em>.
\nWhat they do remember is:<\/p>\n

“The green one I take after lunch.”<\/em>
\n“The yellow strip with the sun logo.”<\/em>
\n“The one that looks like last month\u2019s fever tablets.”<\/em><\/p>\n

These are not trivial details. These are survival strategies.<\/p>\n

When a drug’s identity is only molecular, patients mix it up.<\/p>\n

When it\u2019s visual, distinct, and intuitive \u2014 they get it right.<\/p>\n

So no, identity isn\u2019t a marketing gimmick.<\/p>\n

It\u2019s a safety tool<\/strong>.<\/p>\n

A way to reduce errors, reinforce routine, and return some control to the person on the receiving end of the strip.<\/p>\n

Because healing isn\u2019t just about what\u2019s inside the tablet.<\/p>\n

It\u2019s about making sure the right one is taken \u2014 at the right time \u2014 by the right person.<\/p>\n

That\u2019s why drugs need identity too.<\/strong><\/p>\n

And that\u2019s where Brandcare<\/strong> comes in \u2014 helping pharma brands craft clarity, character, and consistency that patients don\u2019t just see \u2014 but remember.<\/p>\n","protected":false},"excerpt":{"rendered":"

Identity in the Indian pharma business is a curious affair. It begins with a name, navigates a maze of regulatory hurdles, builds momentum with the logo, peaks with the packaging — and then quietly fades away. Somewhere along the assembly line, identity becomes a checkbox, not a commitment. But in a business that trades in … <\/p>\n","protected":false},"author":1,"featured_media":4666,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4648","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-doctalk"],"wps_subtitle":"","_links":{"self":[{"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/posts\/4648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/comments?post=4648"}],"version-history":[{"count":15,"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/posts\/4648\/revisions"}],"predecessor-version":[{"id":4739,"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/posts\/4648\/revisions\/4739"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/media\/4666"}],"wp:attachment":[{"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/media?parent=4648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/categories?post=4648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.brandcare.net\/blog\/wp-json\/wp\/v2\/tags?post=4648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}